Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.

Item

http://www.wikidata.org/entity/Q38155201

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.

@en

type

Item

label

Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.

@en

prefLabel

Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.

@en

P1476

Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.

@en

P2093

Christina Ann Ortmann

http://www.w3.org/2001/XMLSchema#string

Danish Mazhar

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Genome sequencing identifies a basis for everolimus sensitivity

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials

Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.

Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma.

Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

P304

1637-1651

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.13.139

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24156324

http://www.w3.org/2001/XMLSchema#string